Immune Pharmaceuticals Inc  

(Public, NASDAQ:IMNP)   Watch this stock  
Find more results for IMNP
-0.005 (-0.53%)
Oct 20 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.91 - 0.99
52 week 0.88 - 7.15
Open 0.98
Vol / Avg. 1.10M/1.12M
Mkt cap 9.94M
P/E     -
Div/yield     -
EPS -5.60
Shares 10.58M
Beta 2.74
Inst. own 5%

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -95.92% -118.15%
Return on average equity -1091.11% -783.23%
Employees 9 -
CDP Score - -


550 Sylvan Ave Ste 101
United States - Map
+1-201-4642677 (Phone)
+1-917-3981915 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company's segment is acquiring, developing and commercializing prescription drug products. Its Immuno-inflammation product pipeline includes bertilimumab, a fully human antibody targeting eotaxin-1, a regulator of immuno-inflammation; a portfolio of immune oncology products, and NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis. Its immuno-oncology pipeline includes Ceplene, a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.

Officers and directors

Elliot M. Maza J.D., CPA Interim Chief Executive Officer, Director
Age: 61
Bio & Compensation  - Reuters
John Militello CPA Principal Financial Officer, Chief Accounting Officer, Vice President - Finance, Controller
Age: 42
Bio & Compensation  - Reuters
Anthony Fiorino M.D. Ph.D. Chief Operating Officer, Chief Medical Officer
Bio & Compensation  - Reuters
Cameron Durrant M.D. Lead Independent Director
Age: 54
Bio & Compensation  - Reuters
Daniel G. Teper Pharm.D. Director
Age: 55
Bio & Compensation  - Reuters
John A Neczesny Independent Director
Bio & Compensation  - Reuters
Jeffrey Paley M.D. Independent Director
Age: 47
Bio & Compensation  - Reuters